Strong COX-2-expression in hormone-refractory and metastatic prostate cancer — a potential therapeutic target

2004 ◽  
Vol 200 (4) ◽  
pp. 271-272
Author(s):  
F. Bataille ◽  
P. Rümmele ◽  
L.A. Kunz-Schughart ◽  
T. Zellweger ◽  
T.C. Gasser ◽  
...  
Oncotarget ◽  
2014 ◽  
Vol 5 (3) ◽  
pp. 764-774 ◽  
Author(s):  
Francesco Crea ◽  
Akira Watahiki ◽  
Luca Quagliata ◽  
Hui Xue ◽  
Larissa Pikor ◽  
...  

2012 ◽  
Vol 187 (4) ◽  
pp. 1466-1472 ◽  
Author(s):  
Tao Li ◽  
Run-Sheng Li ◽  
Yu-Hua Li ◽  
Shang Zhong ◽  
Yu-Ying Chen ◽  
...  

2010 ◽  
Vol 4 ◽  
pp. CMO.S4477 ◽  
Author(s):  
A.I. Ntekim ◽  
A. Ajekigbe

A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was unexpected, as it is not a known reaction to docetaxel. Hemorrhagic cystitis has been associated with cyclophosphamide, where the metabolite acrolein has been implicated. The mechanism of this reaction from docetaxel is not yet known.


2014 ◽  
Vol 13 (1) ◽  
pp. e3-e3a
Author(s):  
Y. Kawano ◽  
Y. Maeda ◽  
M. Takanobu ◽  
T. Imamura ◽  
W. Takahashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document